In precision medicine, cancer immunotherapy continues to provide new ways to treat patients using the body’s own immune system, and immuno-oncology (I-O) drug development utilizes a combination of scientific and operational expertise. There are many different approaches to I-O development, and we provide novel and innovative immunotherapy laboratory services that combine scientific expertise, innovative technologies, and industry relationships.
Anatomic Pathology | Flow Cytometry and Immunoassays | Genomics |
IHC (single and multiplex) | Immuno-Phenotyping | TCR Immune Sequencing |
Tumor Infiltrating Lymphocytes (TILs) | Receptor Occupancy | Immune Gene Signature / Epigenetic Signatures |
Digital Pathology | Tumor Infiltrating Lymphocytes (TILs) | Digital Spatial Profiling (AP-gene and protein expression) |
FISH | Intracellular Cytokine Survey | Tumor Mutational Burden (TMB) |
Minimal Residual Disease (MRD) | DNA-mismatch repair (MMR) Deficiency | |
Circulating Soluble Proteins | Microsatellite instability (MSI) | |
HLA and KIR typing | ||
Whole Exome Sequencing | ||
NeoAntigen discovery | ||
Microbiome |
We have a broad spectrum of technologies to address biomarker requirements, from early engagement through clinical trial testing and commercialization of assays. Our scientists can work with Translational and Biomarker scientists to develop a biomarker strategy early in clinical development and help deliver the strategy by engaging our team that has proven expertise in executing and delivering science data for I-O clinical development programs.
Service offerings include:
We are a premier global central laboratory service provider for I-O clinical development testing. We have a global central laboratory network including a footprint in the Americas, Europe, Asia-Pacific, and China and a breadth of technological expertise and harmonized processes are available across our laboratories.
Broad Capabilities in Flow Cytometry, Immunoassay, Anatomic Pathology and Genomics:
Integrated science team of experts – Q2 Solutions broad range of scientists and subject matter experts across the company include the following fields:
Certain immuno-oncology programs also have an associated biomarker-based Companion Diagnostics (CDx) program, and Q2 Solutions can provide full support to develop your CDx.
Q2 Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...
If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...
Rules-Based Medicine, a Q2 Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...